STOK Stock Analysis: Stoke Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.037m USD | 12M Return: 182.5% | Charts, Fundamentals & Technical Analysis

Antisense Oligonucleotides, Dravet Syndrome, Optic Atrophy, Genetic Therapies
Total Rating 36
Safety 44
Buy Signal 0.37
Biotechnology
Industry Rotation: +30.9
Market Cap: 2.04B
Avg Turnover: 25.2M
Risk 3d forecast
Volatility76.6%
VaR 5th Pctl11.9%
VaR vs Median-4.77%
Reward TTM
Sharpe Ratio1.86
Rel. Str. IBD85.2
Rel. Str. Peer Group47.8
Character TTM
Beta1.052
Beta Downside0.389
Hurst Exponent0.538
Drawdowns 3y
Max DD71.89%
CAGR/Max DD0.68
CAGR/Mean DD1.61
EPS (Earnings per Share) EPS (Earnings per Share) of STOK over the last years for every Quarter: "2021-06": -0.6, "2021-09": -0.61, "2021-12": -0.66, "2022-03": -0.66, "2022-06": -0.63, "2022-09": -0.66, "2022-12": -0.65, "2023-03": -0.53, "2023-06": -0.69, "2023-09": -0.55, "2023-12": -0.6, "2024-03": -0.57, "2024-06": -0.46, "2024-09": -0.47, "2024-12": -0.18, "2025-03": 1.9, "2025-06": -0.4, "2025-09": -0.65, "2025-12": -0.97, "2026-03": -0.79,
Last SUE: 0.04
Qual. Beats: 0
Revenue Revenue of STOK over the last years for every Quarter: 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 3, 2022-06: 3.231, 2022-09: 2.905, 2022-12: 3.269, 2023-03: 5.152, 2023-06: -2.481, 2023-09: 3.308, 2023-12: 2.802, 2024-03: 4.216, 2024-06: 4.831, 2024-09: 4.894, 2024-12: 22.614, 2025-03: 158.569, 2025-06: 13.817, 2025-09: 10.632, 2025-12: 1.402, 2026-03: 6.229,
Rev. CAGR: 241.20%
Rev. Trend: 80.3%
Last SUE: 0.03
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation

Tailwinds

No distinct edge detected

Seasonality 7 years of data

Jan -6.4% 19
Feb -3.9% 0
Mar -7.4% 16
Apr -10.9% 18
May +5.9% 17
Jun -4.3% 24
Jul +11.8% 22
Aug +0.6% 0
Sep -7.4% 20
Oct +7.3% 36
Nov +1.2% 0
Dec +5.4% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: STOK Stoke Therapeutics

Stoke Therapeutics (NASDAQ: STOK) is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) therapies that upregulate protein expression to treat severe genetic diseases, primarily those caused by haploinsufficiency. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform underpins a pipeline led by zorevunersen (STK-001) for Dravet syndrome, currently in Phase 3, and STK-002 for autosomal dominant optic atrophy, in Phase 1. The company is headquartered in Bedford, Massachusetts, was incorporated in 2014 (formerly ASOthera Pharmaceuticals), and relies on collaboration and licensing agreements with larger partners, including Biogen for zorevunersen and Acadia Pharmaceuticals for RNA-based medicines targeting genetic neurodevelopmental diseases.

As a small-cap biotech with no marketed products, Stoke operates a pre-revenue model typical of the biotechnology sub-industry, funding operations through equity markets and milestone-driven partnerships with major pharmaceutical companies. Its focus on rare, genetically defined central nervous system and ophthalmologic conditions aligns with the broader industry shift toward precision medicines for orphan indications.

Headlines to Watch Out For
  • Zorevunersen Phase 3 Dravet syndrome readout approaches
  • Biogen partnership advances Dravet syndrome commercialization plans
  • STK-002 optic atrophy Phase 1 enrollment progresses
Piotroski VR-10 (Strict) 0.0
Net Income: -169.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.33 > 0.02 and ΔFCF/TA -50.33 > 1.0
NWC/Revenue: 1.02k% < 20% (prev 173.4%; Δ 842.4% < -1%)
CFO/TA -0.33 > 3% & CFO -146.8m > Net Income -169.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.99 > 1.5 & < 3
Outstanding Shares: last quarter (63.1m) vs 12m ago 6.17% < -2%
Gross Margin: 87.07% > 18% (prev 97.69%; Δ -10.63% > 0.5%)
Asset Turnover: 7.55% > 50% (prev 46.92%; Δ -39.37% > 0%)
Interest Coverage Ratio: -49.22 > 6 (EBIT TTM -167.6m / Interest Expense TTM 3.41m)
Altman Z'' 6.71
A: 0.74 (Total Current Assets 366.7m - Total Current Liabilities 40.8m) / Total Assets 443.3m
B: -1.24 (Retained Earnings -547.7m / Total Assets 443.3m)
C: -0.39 (EBIT TTM -167.6m / Avg Total Assets 425.1m)
D: 8.16 (Book Value of Equity 394.9m / Total Liabilities 48.4m)
Altman-Z'' = 6.71 = AAA
Beneish M -0.84
DSRI: 3.0 (Receivables 6.14m/606k, Revenue 32.1m/190.9m)
GMI: 1.12 (GM 97.69% / 87.07%)
AQI: 2.74 (AQ_t 0.16 / AQ_t-1 0.06)
SGI: 0.17 (Revenue 32.1m / 190.9m)
TATA: -0.05 (NI -169.8m - CFO -146.8m) / TA 443.3m)
Beneish M = -0.84 (Cap -4..+1) = D
What is the price of STOK shares?

As of July 08, 2026, the stock is trading at USD 33.02 with a total of 904,585 shares traded. Over the past week, the price has changed by +1.95%, over one month by +13.86%, over three months by -2.25% and over the past year by +182.46%.

Current recommended Stop Loss: 29.70 (which is 10.1% or 2.2 ATR below the current price).

Is STOK a buy, sell or hold?

Stoke Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy STOK.

  • StrongBuy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the STOK price?
Analysts Target Price 45.1 36.6%
Stoke Therapeutics (STOK) - Fundamental Data Overview as of 04 July 2026
Market Cap USD = 2.04b (2.04b USD * 1.0 USD.USD)
P/E Forward = 204.0816
P/S = 63.4854
P/B = 5.1592
Revenue TTM = 32.1m USD
EBIT TTM = -167.6m USD
EBITDA TTM = -164.1m USD
Long Term Debt = 990k USD (estimated: total debt 3.42m - short term 2.43m)
Short Term Debt = 2.43m USD (from shortTermDebt, last quarter)
Debt = 5.86m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.43m
Net Debt = -337.7m USD (calculated: Debt 5.86m - CCE 343.5m)
Enterprise Value = 1.70b USD (2.04b + Debt 5.86m - CCE 343.5m)
Interest Coverage Ratio = -49.22 (Ebit TTM -167.6m / Interest Expense TTM 3.41m)
EV/FCF = -11.50x (Enterprise Value 1.70b / FCF TTM -147.7m)
FCF Yield = -8.69% (FCF TTM -147.7m / Enterprise Value 1.70b)
 FCF Margin = -460.4% (FCF TTM -147.7m / Revenue TTM 32.1m)
 Net Margin = -529.2% (Net Income TTM -169.8m / Revenue TTM 32.1m)
 Gross Margin = 87.07% ((Revenue TTM 32.1m - Cost of Revenue TTM 4.15m) / Revenue TTM)
Gross Margin QoQ = 83.19% (prev 24.75%)
Tobins Q-Ratio = 3.83 (Enterprise Value 1.70b / Total Assets 443.3m)
 Interest Expense / Debt = 58.16% (Interest Expense 3.41m / Debt 5.86m)
 Taxrate = 21.0% (US federal default 21%)
NOPAT = -132.4m (EBIT -167.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.99 (Total Current Assets 366.7m / Total Current Liabilities 40.8m)
Debt / Equity = 0.01 (Debt 5.86m / totalStockholderEquity, last quarter 394.9m)
 Debt / EBITDA = 2.06 (negative EBITDA) (Net Debt -337.7m / EBITDA -164.1m)
 Debt / FCF = 2.29 (negative FCF - burning cash) (Net Debt -337.7m / FCF TTM -147.7m)
 Total Stockholder Equity = 347.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.94% (Net Income -169.8m / Total Assets 443.3m)
RoE = -48.84% (Net Income TTM -169.8m / Total Stockholder Equity 347.6m)
RoCE = -48.09% (EBIT -167.6m / Capital Employed (Equity 347.6m + L.T.Debt 990k))
 RoIC = -32.84% (negative operating profit) (NOPAT -132.4m / Invested Capital 403.3m)
 WACC = 9.65% (E(2.04b)/V(2.04b) * Re(9.68%) + (debt cost/tax rate unavailable))
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 16.23%
 [DCF] Fair Price = unknown (Cash Flow -147.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.04 | # QB: 0
Revenue Correlation: 80.32 | Revenue CAGR: 241.2% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.76 | Chg30d=+6.68% | Revisions=+38% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.81 | Chg30d=+6.56% | Revisions=+38% | Analysts=9
EPS current Year (2026-12-31): EPS=-3.25 | Chg30d=+3.54% | Revisions=+22% | GrowthEPS=-2607.4% | GrowthRev=-85.8%
EPS next Year (2027-12-31): EPS=-3.10 | Chg30d=+2.28% | Revisions=+0% | GrowthEPS=+4.5% | GrowthRev=+76.2%
[Analyst] Revisions Ratio: +32% (up=15, down=7)